One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.
Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, Zubricky R, Karcher H.
Coney JM, et al. Among authors: miller dg.
Clin Ophthalmol. 2023 Nov 23;17:3601-3611. doi: 10.2147/OPTH.S432957. eCollection 2023.
Clin Ophthalmol. 2023.
PMID: 38026599
Free PMC article.